Global Open-Label Extension Study of Del-desiran for the Treatment of DM1
Status:
ENROLLING_BY_INVITATION
Trial end date:
2030-10-01
Target enrollment:
Participant gender:
Summary
A Global Phase 3 Open-Label Extension Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Intravenous Delpacibart Etedesiran (abbreviated del-desiran, formerly AOC 1001) for the Treatment of Myotonic Dystrophy Type 1